JAK2 and glioblastoma: This aligns with prior reports: JAK2/STAT3 inhibition (e.g., AG490) suppresses EGFRvIII-driven invasion in GBM [34], while VEGF-A blockade counteracts myeloid-derived suppressor cell (MDSC) differentiation [35].